The funding will accelerate the development and regulatory clearance of VIOSync SPI, an AI-powered clinical decision support platform that predicts in-hospital sepsis development within the next 48 hours.
Aisthesis Medical, a UK-based healthtech startup developing hospital-grade AI clinical decision-support software, today announced the successful closing of a $1.2M (£900K) pre-seed funding round, led by TwinPath Ventures with participation from TECS Capital. The funding will accelerate the development and regulatory clearance of VIOSync SPI, an AI-powered clinical decision support platform that predicts in-hospital sepsis development within the next 48 hours.
Sepsis is one of the world’s most urgent healthcare challenges, causing over 11 million deaths each year and costing healthcare systems billions. Early detection and timely intervention are critical but frontline clinicians often lack the tools to identify the onset of sepsis before deterioration occurs.
VIOSync Sepsis Prediction Index (SPI) addresses this gap by securely ingesting multimodal patient data from hospital systems, creating a digital twin of the patient’s evolving physiology. Using explainable AI algorithms, the platform predicts the onset of sepsis within the next 48 hours, providing clinicians with transparent risk drivers and actionable insights to intervene earlier and save lives.
This investment will support Aisthesis Medical’s mission to empower clinicians with trusted, explainable AI tools that can prevent life-threatening patient deterioration. The funding will be used to advance CE MDR submission for VIOSync SPI and expand clinical validation studies across leading hospitals in the UK and EU. The company also plans to strengthen its team, with a view to expanding the product’s reach and preparing for NHS and international pilot deployments.
Ioannis Gkouzionis, Co-founder & CEO of Aisthesis Medical, said:
“I’ve lived through sepsis twice. I know how quickly stability becomes a crisis and how much an earlier insight can change the outcome. With VIOSync we’re giving clinicians a trusted, explainable way to predict risk before symptoms emerge, enabling faster decisions and ultimately saving lives. This funding is a strong validation of our mission and will help us accelerate both regulatory approvals and clinical adoption.”
Katie Lockwood, Partner, Twin Path Ventures commented:
“Sepsis is a silent killer that has long lacked predictive tools clinicians can trust. Aisthesis Medical’s combination of explainable AI, multimodal data integration, and digital twin technology is uniquely positioned to set a new standard in sepsis care. We are proud to back this exceptional team as they take the next steps towards regulatory approval and market launch.”
Antonis Ilias, Partner, TECS Capital commented:
“Backing Aisthesis Medical as our first investment in TECS Capital II reflects exactly the kind of impact-driven, deep-tech entrepreneurship we stand for. Transforming sepsis prediction with explainable AI goes beyond innovation, representing a life-saving shift in clinical practice. With clinical validation underway in the UK and EU and a disciplined path toward CE MDR approval, we’re proud to support an exceptional founding team in bringing this product to market.”
About Aisthesis Medical
Aisthesis Medical is a UK-based healthtech startup company founded in 2022 by Ioannis Gouzionis, Vasilis Dimakopoulos and Sotiris Liliopoulos with the aim to develop hospital-grade AI software to predict and prevent life-threatening conditions. With PhDs in artificial intelligence from top-notch European Universities like Imperial College London and ETH Zurich but also expertise from leading industrial entities, the founding team developed VIOSync SPI, a medical device software that predicts in-hospital sepsis development. The founding team is supported by Dr Savvas Vlachos, an experienced NHS ICU Consultant and Clinial Lead at Aisthesis Medical, ensuring the technology is grounded in frontline clinical practice. Accompanied in their journey with a team of expert advisors namely Jeff Pompeo, Paul Morton, Erki Molder and Anthology Ventures, Aishesis Medical aims into becoming the leading company in sepsis prognosis a step before diagnosis offering a critical advantage over the competing solutions. Aisthesis Medical currently partners with leading hospitals across the UK and EU to clinically validate and deploy its technology, with a mission to help clinicians to change the narrative to proactive prevention.
About Twin Path Ventures
Twin Path Ventures is a London-based pre-seed/seed venture firm investing in AI-first, deep-tech startups. The fund backs highly technical founding teams and frontier AI research with the aim of translating breakthroughs into real-world products.
About TECS Capital
TECS Capital is a Greek venture capital fund investing at the pre-seed stage in deep-tech and transformative startups, backing visionary founders who develop breakthrough technology products with global potential.